FMP
Quoin Pharmaceuticals, Ltd.
QNRX
NASDAQ
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
0.638 USD
0.0076 (1.19%)
About
ceo
Dr. Michael Myers Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://quoinpharma.com
exchange
NASDAQ
Description
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
CIK
0001671502
ISIN
US74907L3006
CUSIP
74907L102
Address
42127 Pleasant Forest Court
Phone
703 980 4182
Country
US
Employee
4
IPO Date
Aug 1, 2016
Key Executives
